By: Benzinga
UPDATE: Piper Jaffray Initiates Coverage on Alexza Pharmaceuticals to Neutral Rating, $5 PT
In a report published Friday, Piper Jaffray & Co. initiated coverage on Alexza Pharmaceuticals (NASDAQ: ALXA ) with a Neutral rating and $5.00 price target. Piper Jaffray noted, “We are initiating coverage on Alexza with a Neutral rating and 12-month price target of $5. Alexza reformulates drugs for pulmonary delivery
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here